



**Todd Kremin**

**From:** Henry Warner  
**Sent:** Monday, June 05, 2006 10:52 AM  
**To:** 'Matt Samuel'  
**Cc:** Robert Trumpy; 'Andrew B. Worden'  
**Subject:** RE: Biosafe Medical Letter of Intent

Matt:

Thanks for the LOI. Before I forward this on to legal and accounting, let me ask 2 quick questions:

1. In talking to Andrew, I understood that Barron's valuation formula uses a 7 multiple applied to a corrected EBITDA. With a \$1.85M EBITDA less \$400,000 in new "public costs" and \$180,000 in recurring capital, I get a corrected EBITDA of \$1.27. This number times 7 gives a cap of approximately \$8.9M. Your proposal appears to be valued at approximately \$5M. Please explain what I have misunderstood.
2. In correcting EBITDA for the public entity, a credit of \$180,000 in "recurring capital expenditures" is listed. Did this come from our numbers? Please explain what this is.

Thanks,

*Hank*

Henry A. Warner  
Chief Executive Officer  
BIOSAFE Medical Technologies, inc.  
847-234-8111

---

**From:** Matt Samuel [mailto:mcs@barronpartners.com]  
**Sent:** Friday, June 02, 2006 1:08 PM  
**To:** Henry Warner  
**Cc:** Robert Trumpy; 'Andrew B. Worden'  
**Subject:** Biosafe Medical Letter of Intent

Mr. Warner,

I have attached the Barron Partners letter of Intent for Biosafe Medical Technologies. Please review the terms, and feel free to contact me with any questions. Thank you for your time and we look forward to becoming your financial partner.

Regards,

Matthew C T Samuel  
Junior Analyst  
Barron Partners LP  
730 Fifth Avenue, 25th Floor  
New York, NY 10019  
tel: 212-359-0205  
fax: 646-607-2223  
[mcs@barronpartners.com](mailto:mcs@barronpartners.com)  
[www.barronpartners.com](http://www.barronpartners.com)

The information contained in this communication may be confidential, is intended only for the use of the recipient named above, and may be legally privileged. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this communication in error, please re-send this communication to the sender and delete the original message and any copy of it from your computer system. Thank you.

4/28/2008

Exhibit 12